Empagliflozin(864070-44-0)Blood glucose reduction API

Empagliflozin is an oral, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor primarily indicated for the management of type 2 diabetes. By blocking glucose reabsorption in the kidneys, it promotes the excretion of excess sugar through urine, effectively lowering blood glucose levels independently of insulin. Beyond its glycemic control benefits, Empagliflozin has demonstrated profound cardiovascular and renal protective effects. It significantly reduces the risk of cardiovascular death and hospitalization for heart failure, and slows the progression of chronic kidney disease (CKD) in eligible patients, making it a cornerstone therapy in modern metabolic and cardiovascular medicine.